Patient-Derived Xenograft/PDX Model Market

Patient-Derived Xenograft/PDX Model Market worth $839 million by 2028

The report "Patient-Derived Xenograft/PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028", is projected to reach USD 839 million by 2028 from USD 426 million in 2023, at a CAGR of 14.5% during the forecast period. Some of the prominent factors driving the growth of this market are the accuracy of drug testing, rising demand for personalized medicine, and the usefulness of PDX models to identify relevant biomarkers for disease diagnosis. However, significant operational costs associated with patient derived xenograft/ PDX model are expected to restrain market growth to a certain extent.

Browse 261 market data Tables and 35 Figures spread through 248 Pages and in-depth TOC on "Patient-Derived Xenograft/PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/patient-derived-xenograft-model-market-121598251.html

Mouse model type accounted for the largest share of the patient-derived xenograft/ PDX model market.

Among the types, the patient-derived xenograft/ PDX model market is segmented into mouse model, and rat model. In 2023, the mouse model segment accounted for the largest share of the patient-derived xenograft/ PDX model market. Growth in this market segment can be attributed to biological similarities of the mice model with human tumors, and the availability of immunodeficient strains is expected to form the largest share segment in the patient derived xenograft/ PDX model market.

The respiratory tumor type segment is the fastest-growing segment of the patient derived xenograft/ PDX model market.

In 2023, the respiratory tumor type segment accounted for the fastest-growing share of the tumor type segment of the patient derived xenograft/ PDX model market. Market growth can largely be attributed to the rising prevalence of lung cancer. The market is also driven by increasing focus on the drug development of respiratory tumor models after the COVID-19 pandemic.

Asia Pacific: The fastest-growing region in the patient derived xenograft/ PDX model market.

The Asia Pacific patient derived xenograft/ PDX model market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of precision medicine and a rise in the number of drug development processes. The Asian market has also garnered significant attention from global players due to the increasing pharmaceutical R&D spending, and the growing trend of outsourcing drug discovery services.

The market for patient-derived xenograft/ PDX models is highly fragmented, with key players strategizing to capture a majority of the market. Prominent players in the market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

Don’t miss out on business opportunities in Patient-Derived Xenograft/PDX Model Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Patient-Derived Xenograft/PDX Model Market Size,  Share & Growth Report
Report Code
BT 5576
PR Published ON
8/30/2023
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Patient-Derived Xenograft/PDX Model Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
...

Digital Virtual Assistant - MarketsandMarkets

Home